* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Changes to Exempt Dealings - Office of the Gene Technology
Survey
Document related concepts
Nucleic acid analogue wikipedia , lookup
Public health genomics wikipedia , lookup
Human genetic variation wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Genome (book) wikipedia , lookup
Microevolution wikipedia , lookup
Gene therapy wikipedia , lookup
Human–animal hybrid wikipedia , lookup
Genomic library wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Genetically modified food wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Genetic engineering wikipedia , lookup
Genetically modified organism containment and escape wikipedia , lookup
Transcript
May 2007 CHANGES TO EXEMPT DEALINGS What sort of containment do exempt dealings require ? From 1 July 2007 the only legislative requirement for exempt dealings is that they do not involve the intentional release of GMOs into the environment. From July 1 2007 exempt dealings do not require a specified level of containment. However, guidance on the appropriate containment for exempt dealings may be found on the OGTR website at www.ogtr.gov.au/pdf/certification/ExemptDealGuide.pdf. What sort of reporting is required for exempt dealings ? From 1 July 2007 there are no requirements to report to the Gene Technology Regulator on exempt dealings. Which Exempt dealings are now Notifiable Low Risk Dealings (NLRDs) ? After 31 March 2007, a number of NLRDs were reclassified as exempt dealings and therefore needed to be contained according to the Regulator’s guidelines (in PC1 or equivalent facilities). Following removal of containment requirements for exempt dealings from 1 July 2007, a small number are now classified as ‘PC1 NLRDs’ to maintain containment and regulatory oversight. From 1 July 2007, the following dealings must be conducted in facilities certified to PC1 (or above)1: (a) a dealing involving a genetically modified laboratory mouse or a genetically modified laboratory rat, unless: (i) an advantage is conferred on the animal by the genetic modification; or (ii) because of the genetic modification, the animal is capable of secreting or producing an infectious agent; (b) a dealing involving a host/vector system mentioned in Part 2 of Schedule 2 (i.e. in vitro dealings with non-viral vectors or defective viral vectors unable to transduce human cells) if the donor nucleic acid confers an oncogenic modification; (c) a dealing involving a defective viral vector able to transduce human cells in a host mentioned in item 4 of Part 2 of Schedule 2 (animal or human cell culture), unless: (i) the vector is a retroviral vector; or (ii) the donor nucleic acid confers an oncogenic modification. [Part 1, Schedule 3 Gene Technology Regulations 2001 as amended 2007] Do I need to obtain a new approval for a reclassified PC1 NLRD ? No. If your NLRD was notified prior to 31 March 2007, the NLRD authority remains and you do not need to apply again if it is now reclassified as a ‘PC1’ NLRD. However, if you have (or will commence work on) a dealing that was classified as an exempt dealing after 31 March 2007, you DO need to obtain approval from your IBC. More information about the changes can be obtained from the Office of the Gene Technology Regulator website at www.ogtr.gov.au, by email to [email protected] or by telephoning 1800 181 030 1 All existing OGTR-certified facilities should already meet the necessary containment requirements and therefore may continue to be used for these dealings.